TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES SUBUNIT VACCINES Applications of Subunit Vaccines TABLE 8 APPLICATIONS OF
|
|
- Diana Hensley
- 6 years ago
- Views:
Transcription
1 CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED BCC RESEARCH REPORTS... 3 BCC ONLINE SERVICES... 4 DISCLAIMER... 4 CHAPTER TWO: EXECUTIVE SUMMARY... 5 EXECUTIVE SUMMARY... 5 SUMMARY TABLE GLOBAL REVENUE OF HUMAN AND ANIMAL VACCINES, THROUGH 2015 ($ MILLIONS)... 6 SUMMARY FIGURE GLOBAL REVENUE OF HUMAN AND ANIMAL VACCINES, ($ MILLIONS)... 7 CHAPTER THREE: OVERVIEW... 8 WHAT IS A VACCINE?... 8 HISTORY OF VACCINES... 8 TABLE 1 HISTORY OF VACCINES, TABLE 1 (CONTINUED)... 9 TYPES OF VACCINES... 9 ATTENUATED (LIVE) VACCINES... 9 Applications of Attenuated (Live) Vaccines TABLE 2 APPLICATIONS OF ATTENUATED (LIVE) VACCINES Advantages and Disadvantages of Attenuated (Live) Vaccines TABLE 3 ADVANTAGES AND DISADVANTAGES OF ATTENUATED (LIVE) VACCINES TABLE 3 (CONTINUED) INACTIVATED (KILLED) VACCINES Applications of Inactivated (Killed) Vaccines TABLE 4 APPLICATIONS OF INACTIVATED (KILLED) VACCINES TABLE 4 (CONTINUED) Advantages and Disadvantages of Inactivated (Killed) Vaccines TABLE 5 ADVANTAGES AND DISADVANTAGES OF INACTIVED (KILLED) VACCINES TOXOID VACCINES Applications of Toxoid Vaccines TABLE 6 APPLICATIONS OF TOXOID VACCINES Advantages and Disadvantages of Toxoid Vaccines... 13
2 TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES SUBUNIT VACCINES Applications of Subunit Vaccines TABLE 8 APPLICATIONS OF SUBUNIT VACCINES Advantages and Disadvantages of Subunit Vaccines TABLE 9 ADVANTAGES AND DISADVANTAGES OF SUBUNIT VACCINES CONJUGATE VACCINES Applications of Conjugate Vaccines TABLE 10 APPLICATIONS OF CONJUGATE VACCINES Advantages and Disadvantages of Conjugate Vaccines TABLE 11 ADVANTAGES AND DISADVANTAGES OF CONJUGATE VACCINES RECOMBINANT VECTOR VACCINES Applications of Recombinant Vector Vaccines TABLE 12 APPLICATIONS OF RECOMBINANT VECTOR VACCINES Advantages and Disadvantages of Recombinant Vector Vaccines TABLE 13 ADVANTAGES AND DISADVANTAGES OF RECOMBINANT VECTOR VACCINES DNA VACCINES Applications of DNA Vaccines TABLE 14 APPLICATIONS OF DNA VACCINES Advantages and Disadvantages of DNA Vaccines TABLE 15 ADVANTAGES AND DISADVANTAGES OF DNA VACCINES INFECTIOUS DISEASES PREVENTABLE BY VACCINES HUMAN DISEASES Viral Diseases TABLE 16 VACCINE PREVENTABLE HUMAN VIRAL DISEASES TABLE 16 (CONTINUED) TABLE 16 (CONTINUED) Bacterial Diseases TABLE 17 VACCINE PREVENTABLE HUMAN BACTERIAL DISEASES TABLE 17 (CONTINUED) TABLE 17 (CONTINUED) ANIMAL DISEASES TABLE 18 VACCINE PREVENTABLE ANIMAL DISEASES IN COMPANION ANIMALS TABLE 18 (CONTINUED) TABLE 19 VACCINE PREVENTABLE ANIMAL DISEASES IN LIVESTOCK ANIMALS TABLE 19 (CONTINUED)... 26
3 TABLE 20 LIVESTOCK ANIMAL VACCINES TABLE 20 (CONTINUED) TABLE 20 (CONTINUED) TABLE 20 (CONTINUED) TABLE 20 (CONTINUED) TABLE 20 (CONTINUED) TABLE 20 (CONTINUED) TABLE 20 (CONTINUED) TABLE 20 (CONTINUED) CHAPTER FOUR: PREVALENCE INCIDENCE AND IMMUNIZATION OF HUMAN DISEASES REGIONAL DATA TABLE 21 REPORTED INCIDENCE DATA OF HUMAN DISEASES, BY REGION, TABLE 21 (CONTINUED) TABLE 22 IMMUNIZATION COVERAGE DATA OF HUMAN DISEASES, BY REGION, (%) TABLE 22 (CONTINUED) GLOBAL DATA TABLE 23 REPORTED CASES OF HUMAN DISEASES, 2007 AND TABLE 24 IMMUNIZATION COVERAGE OF HUMAN DISEASES (%) GLOBAL IMMUNIZATION UPTAKE DATA TABLE 25 UPTAKE OF NEW AND UNDERUSED VACCINES, GLOBAL DEATHS DUE TO VACCINE PREVENTABLE DISEASES TABLE 26 GLOBAL CHILD DEATHS DUE TO VACCINE PREVENTABLE DISEASES, CHAPTER FIVE: REGULATORY ASPECTS TABLE 27 REVISIONS TO EXISTING VACCINES, TABLE 27 (CONTINUED) TABLE 27 (CONTINUED) TABLE 27 (CONTINUED) TABLE 27 (CONTINUED) TABLE 27 (CONTINUED) TABLE 28 NEW VACCINES IN THE GLOBAL MARKET, TABLE 28 (CONTINUED) TABLE 28 (CONTINUED) TABLE 28 (CONTINUED) TABLE 28 (CONTINUED) CHAPTER SIX: INDUSTRY STRUCTURE WHO PREQUALIFIED VACCINE MANUFACTURERS/SUPPLIERS... 52
4 TABLE 29 WORLD HEALTH ORGANIZATION (WHO) PREQUALIFIED MANUFACTURERS/SUPPLIERS OF HUMAN VACCINES, TABLE 29 (CONTINUED) MANUFACTURERS/SUPPLIERS OF HUMAN VACCINES ATTENUATED (LIVE) VACCINES TABLE 30 LEADING MANUFACTURERS/SUPPLIERS OF ATTENUATED (LIVE) VACCINES TABLE 30 (CONTINUED) INACTIVATED (KILLED) VACCINES TABLE 31 LEADING MANUFACTURERS/SUPPLIERS OF INACTIVATED (KILLED) VACCINES CONJUGATE VACCINES TABLE 32 LEADING MANUFACTURERS/SUPPLIERS OF CONJUGATE VACCINES RECOMBINANT / RECOMBINANT DNA (RDNA) VACCINES TABLE 33 LEADING MANUFACTURERS/SUPPLIERS OF RECOMBINANT/ RECOMBINANT DNA (RDNA) VACCINES TABLE 33 (CONTINUED) SUBUNIT VACCINES TABLE 34 LEADING MANUFACTURERS/SUPPLIERS OF SUBUNIT VACCINES TOXOID VACCINES TABLE 35 LEADING MANUFACTURERS/SUPPLIERS OF TOXOID VACCINES COMBINATION VACCINES TABLE 36 LEADING MANUFACTURERS/SUPPLIERS OF COMBINATION VACCINES MARKET SHARES OF INDUSTRY LEADERS OF HUMAN VACCINES ATTENUATED (LIVE) VACCINES TABLE 37 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ATTENUATED (LIVE) VACCINES, 2009 (%) FIGURE 1 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ATTENUATED (LIVE) VACCINES, 2009 (%) INACTIVATED (KILLED) VACCINES TABLE 38 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF INACTIVATED (KILLED) VACCINES, 2009 (%) FIGURE 2 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF INACTIVATED (KILLED) VACCINES, 2009 (%) CONJUGATE VACCINES... 62
5 TABLE 39 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF CONJUGATE VACCINES, 2009 (%) FIGURE 3 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF CONJUGATE VACCINES, 2009 (%) RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES TABLE 40 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES, 2009 (%) FIGURE 4 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES, 2009 (%) SUBUNIT VACCINES TABLE 41 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SUBUNIT VACCINES, 2009 (%) FIGURE 5 GLOBAL MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF SUBUNIT VACCINES, 2009 (%) TOXOID VACCINES TABLE 42 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF TOXOID VACCINES, 2009 (%) FIGURE 6 GLOBAL MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF TOXOID VACCINES, 2009 (%) COMBINATION VACCINES TABLE 43 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF COMBINATION VACCINES, 2009 (%) FIGURE 7 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF COMBINATION VACCINES, 2009 (%) CHAPTER SEVEN: NEW DEVELOPMENTS NEW DEVELOPMENTS TABLE 44 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF HUMAN VACCINES (AS OF AUGUST 2010) TABLE 44 (CONTINUED) TABLE 44 (CONTINUED) TABLE 44 (CONTINUED) TABLE 44 (CONTINUED) TABLE 44 (CONTINUED) CHAPTER EIGHT: MARKET ANALYSIS: HUMAN... 75
6 TABLE 45 GLOBAL MARKET FOR HUMAN VACCINES BY REGION, THROUGH 2015 ($ MILLIONS) FIGURE 8 GLOBAL MARKET FOR HUMAN VACCINES BY REGION, ($ MILLIONS) ATTENUATED (LIVE) VACCINES MARKET OVERVIEW MARKET REVENUE TABLE 46 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINES, BY REGION, THROUGH 2015 ($ MILLIONS) FIGURE 9 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINES, BY REGION, ($ MILLIONS) INACTIVATED (KILLED) VACCINES MARKET OVERVIEW MARKET REVENUE TABLE 47 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES, THROUGH 2015 ($ MILLIONS) FIGURE 10 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES, ($ MILLIONS) CONJUGATE VACCINES MARKET OVERVIEW MARKET REVENUE TABLE 48 GLOBAL MARKET FOR CONJUGATE VACCINES, THROUGH 2015 ($ MILLIONS) FIGURE 11 GLOBAL MARKET FOR CONJUGATE VACCINES, ($ MILLIONS) RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES MARKET OVERVIEW MARKET REVENUE TABLE 49 GLOBAL MARKET FOR RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES, THROUGH 2015 ($ MILLIONS) FIGURE 12 GLOBAL MARKET FOR RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES, ($ MILLIONS) SUBUNIT VACCINES MARKET OVERVIEW MARKET REVENUE TABLE 50 GLOBAL MARKET FOR SUBUNIT VACCINES, THROUGH 2015 ($ MILLIONS) FIGURE 13 GLOBAL MARKET FOR SUBUNIT VACCINES, ($ MILLIONS) TOXOID VACCINES MARKET OVERVIEW MARKET REVENUE TABLE 51 GLOBAL MARKET FOR TOXOID VACCINES, THROUGH 2015 ($ MILLIONS)... 91
7 FIGURE 14 GLOBAL MARKET FOR TOXOID VACCINES, ($ MILLIONS) COMBINATION VACCINES MARKET OVERVIEW MARKET REVENUE TABLE 52 GLOBAL MARKET FOR COMBINATION VACCINES, BY REGION THROUGH 2015 ($ MILLIONS) FIGURE 15 GLOBAL MARKET FOR COMBINATION VACCINES, BY REGION, ($ MILLIONS) MARKET SHARES OF HUMAN VACCINES, BY REGION TABLE 53 GLOBAL HUMAN VACCINES MARKET SHARES BY REGION, 2009 (%) FIGURE 16 GLOBAL HUMAN VACCINES MARKET SHARES BY REGION, 2009 (%) MARKET SHARES OF HUMAN VACCINES, BY TYPE TABLE 54 GLOBAL HUMAN VACCINES MARKET SHARES BY VACCINE TYPE, 2009 (%) FIGURE 17 GLOBAL HUMAN VACCINES MARKET SHARES BY VACCINE TYPE, 2009 (%) CHAPTER NINE: ANIMAL HEALTH MARKET INDUSTRY MANUFACTURERS OF ANIMAL HEALTH PRODUCTS MARKET OVERVIEW MARKET REVENUE TABLE 55 GLOBAL ANIMAL HEALTH REVENUES BY MARKET LEADERS, ($ MILLIONS) TABLE 56 GLOBAL ANIMAL HEALTH MARKET SHARES BY REVENUE, 2009 (%) FIGURE 18 GLOBAL ANIMAL HEALTH MARKET SHARES BY REVENUE, 2009 (%) ANIMAL VACCINES TABLE 57 GLOBAL MARKET FOR ANIMAL VACCINES, THROUGH 2015 ($ MILLIONS) FIGURE 19 GLOBAL MARKET FOR ANIMAL VACCINES, ($ MILLIONS) CHAPTER TEN: MARKET BY APPLICATIONS HUMANS TABLE 58 DISEASES AND INFECTIONS WITH DEVELOPED HUMAN VACCINES BASED ON MICROORGANISM TABLE 59 DISEASES AND INFECTIONS WITH DEVELOPED HUMAN VACCINES BASED ON TREATMENT MENINGOCOCCAL/PNEUMOCOCCAL DISEASES MARKET REVENUE
8 TABLE 60 GLOBAL SALES OF HUMAN VACCINES IN MENINGOCOCCAL/ PNEUMOCOCCAL DISEASES MARKET, THROUGH 2015 ($ MILLIONS) FIGURE 20 GLOBAL SALES OF HUMAN VACCINES IN MENINGOCOCCAL/ PNEUMOCOCCAL DISEASES MARKET, ($ MILLIONS) TABLE 61 TOP SELLING GROUPS OF MENINGOCOCCAL/ PENUMOCOCCAL VACCINES FOR 2009 BY MARKET SHARE (%) INFLUENZA (SEASONAL AND PANDEMIC) DISEASES MARKET REVENUE TABLE 62 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET, THROUGH 2015 ($ MILLIONS) FIGURE 21 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET, ($ MILLIONS) TABLE 63 TOP SELLING GROUPS OF INFLUENZA VACCINES BY MARKET SHARE, 2009 (%) PEDIATRIC/POLIO/PERTUSSIS/HIB DISEASES MARKET REVENUE TABLE 64 GLOBAL SALES OF HUMAN VACCINES IN PEDIATRIC/POLIO PERTUSSIS/HIB DISEASES MARKET, THROUGH 2015 ($ MILLIONS) FIGURE 22 GLOBAL SALES OF HUMAN VACCINES IN PEDIATRIC/ POLIO/PERTUSSIS/HIB DISEASES MARKET, ($ MILLIONS) TABLE 65 TOP SELLING GROUPS OF PEDIATRIC/POLIO/PERTUSSIS/HIB VACCINES BY MARKET SHARE, 2009 (%) ADULT/ADOLESCENT BOOSTER RELATED DISEASES MARKET REVENUE TABLE 66 GLOBAL SALES OF HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER RELATED DISEASES MARKET, THROUGH 2015 ($ MILLIONS) FIGURE 23 GLOBAL SALES OF HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER RELATED DISEASES MARKET, ($ MILLIONS) TABLE 67 TOP SELLING GROUPS OF ADULT/ADOLESCENT BOOSTER RELATED VACCINES BY MARKET SHARE, 2009 (%) TRAVEL AND OTHER ENDEMIC DISEASES MARKET REVENUE TABLE 68 GLOBAL SALES OF HUMAN VACCINES IN TRAVEL AND OTHER ENDEMIC DISEASES MARKET, THROUGH 2015 ($ MILLIONS) FIGURE 24 GLOBAL SALES OF HUMAN VACCINES IN TRAVEL AND OTHER ENDEMIC DISEASES MARKET, ($ MILLIONS)
9 TABLE 69 TOP SELLING GROUPS OF TRAVEL AND OTHER ENDEMIC VACCINES BY MARKET SHARE, 2009 (%) HPV DISEASE MARKET REVENUE TABLE 70 GLOBAL SALES OF HUMAN VACCINES IN HPV DISEASE MARKET, THROUGH 2015 ($ MILLIONS) FIGURE 25 GLOBAL SALES OF HUMAN VACCINES IN HPV DISEASE MARKET, ($ MILLIONS) TABLE 71 TOP SELLING HPV VACCINES IN THE ORDER OF THEIR SALES, 2009 (%) ROTAVIRUS DISEASE MARKET REVENUE TABLE 72 GLOBAL SALES OF HUMAN VACCINES IN ROTAVIRUS DISEASE MARKET, THROUGH 2015 ($ MILLIONS) FIGURE 26 GLOBAL SALES OF HUMAN VACCINES IN ROTAVIRUS DISEASE MARKET, ($ MILLIONS) TABLE 73 TOP SELLING ROTAVIRUS VACCINES BY MARKET SHARE, 2009 (%) OTHER DISEASES MARKET REVENUE TABLE 74 GLOBAL SALES OF HUMAN VACCINES IN OTHER DISEASES MARKET, THROUGH 2015 ($ MILLIONS) FIGURE 27 GLOBAL SALES OF HUMAN VACCINES IN OTHER DISEASES MARKET, ($ MILLIONS) TABLE 75 TOP SELLING OTHER VACCINES FOR 2009 BY MARKET SHARE (%) MARKET SHARE OF APPLICATIONS TABLE 76 SHARE OF VARIOUS CATEGORIES OF VACCINES IN THE HUMAN VACCINES MARKET, 2009 (%) FIGURE 28 SHARE OF VARIOUS CATEGORIES OF VACCINES IN THE HUMAN VACCINES MARKET, 2009 (%) CHAPTER ELEVEN: PATENT ANALYSIS TOTAL NUMBER OF PATENTS TABLE 77 NUMBER OF SIGNIFICANT PATENTS, 2006 TO SEPTEMBER FIGURE 29 NUMBER OF SIGNIFICANT PATENTS, 2006 TO SEPTEMBER FIGURE 30 PERCENT OF SIGNIFICANT PATENTS, 2006 TO SEPTEMBER 2010 (%) PATENTS BY TYPE AND YEAR TABLE 78 PATENTS BY TECHNOLOGY, 2006 TO SEPTEMBER FIGURE 31 PATENTS BY TECHNOLOGY, 2006 TO SEPTEMBER PATENTS BY COMPANY INACTIVATED (KILLED) VACCINE TECHNOLOGY
10 TABLE 79 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING INACTIVATED (KILLED) VACCINE TECHNOLOGY, 2006 TO SPETEMBER FIGURE 32 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING INACTIVATED (KILLED) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER ATTENUATED (LIVE) VACCINE TECHNOLOGY TABLE 80 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING ATTENUATED (LIVE) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER FIGURE 33 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING ATTENUATED (LIVE) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER CONJUGATE VACCINE TECHNOLOGY TABLE 81 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING CONJUGATE VACCINE TECHNOLOGY, 2006 TO SEPTEMBER FIGURE 34 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING CONJUGATE VACCINE TECHNOLOGY, 2006 TO SEPTEMBER TOXOID VACCINE TECHNOLOGY TABLE 82 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING TOXOID VACCINE TECHNOLOGY, 2006 TO SEPTEMBER FIGURE 35 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING TOXOID VACCINE TECHNOLOGY, 2006 TO SEPTEMBER RECOMBINANT/RDNA VACCINE TECHNOLOGY TABLE 83 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING RECOMBINANT/RDNA VACCINE TECHNOLOGY, 2006 TO SEPTEMBER TABLE 83 (CONTINUED) FIGURE 36 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING RECOMBINANT/RDNA VACCINE TECHNOLOGY, 2006 TO SEPTEMBER SUBUNIT VACCINE TECHNOLOGY TABLE 84 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING SUBUNIT VACCINE TECHNOLOGY, 2006 TO SEPTEMBER FIGURE 37 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING SUBUNIT VACCINE TECHNOLOGY, 2006 TO SEPTEMBER OTHER/COMBINED VACCINE TECHNOLOGY TABLE 85 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING OTHER/COMBINED VACCINE TECHNOLOGY, 2006 TO SEPTEMBER TABLE 85 (CONTINUED)
11 FIGURE 38 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING OTHER/ COMBINED VACCINE TECHNOLOGY, 2006 TO SEPTEMBER PATENTS BY COUNTRY INACTIVATED (KILLED) VACCINE TECHNOLOGY TABLE 86 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING INACTIVATED (KILLED) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER FIGURE 39 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING INACTIVATED (KILLED) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER ATTENUATED (LIVE) VACCINE TECHNOLOGY TABLE 87 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING ATTENUATED (LIVE) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER TABLE 87 (CONTINUED) FIGURE 40 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING ATTENUATED (LIVE) VACCINE TECHNOLOGY, CONJUGATE VACCINE TECHNOLOGY TABLE 88 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING CONJUGATE VACCINE TECHNOLOGY, 2006 TO SEPTEMBER FIGURE 41 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING CONJUGATE VACCINE TECHNOLOGY, 2006 TO SEPTEMBER TABLE 89 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING TOXOID VACCINE TECHNOLOGY, 2006 TO SEPTEMBER FIGURE 42 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING TOXOID VACCINE TECHNOLOGY, 2006 TO SEPTEMBER RECOMBINANT/ DNA/ RDNA VACCINE TECHNOLOGY TABLE 90 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING RECOMBINANT/DNA/RDNA VACCINE TECHNOLOGY, 2006 TO SEPTEMBER FIGURE 43 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING RECOMBINANT/DNA/RDNA VACCINE TECHNOLOGY, 2006 TO SEPTEMBER SUBUNIT VACCINE TECHNOLOGY TABLE 91 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING SUBUNIT VACCINE TECHNOLOGY, 2006 TO SEPTEMBER FIGURE 44 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING SUBUNIT VACCINE TECHNOLOGY, 2006 TO SEPTEMBER OTHER/COMBINED VACCINE TECHNOLOGY
12 TABLE 92 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING OTHER/COMBINED VACCINE TECHNOLOGY, 2006 TO SEPTEMBER FIGURE 45 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING OTHER/COMBINED VACCINE TECHNOLOGY, 2006 TO SEPTEMBER TABLE 93 NUMBER OF U.S. PATENTS BY COUNTRY FOR ALL VACCINE TYPES, 2006 TO SEPTEMBER 2010 (%) TABLE 93 (CONTINUED) FIGURE 46 PATENT SHARES BY COUNTRY FOR VACCINES, 2006 TO SEPTEMBER 2010 (%) PATENTS BY ASSIGNEE INACTIVATED (KILLED) VACCINE TECHNOLOGY TABLE 94 PATENTS BY ASSIGNEE UTILIZING INACTIVATED (KILLED) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER FIGURE 47 PATENTS BY ASSIGNEE UTILIZING INACTIVATED (KILLED) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER ATTENUATED (LIVE) VACCINE TECHNOLOGY TABLE 95 PATENTS BY ASSIGNEE UTILIZING ATTENUATED (LIVE) VACCINE TECHNOLOGY, 2006 THROUGH SEPTEMBER FIGURE 48 PATENTS BY ASSIGNEE UTILIZING ATTENUATED (LIVE) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER CONJUGATE VACCINE TECHNOLOGY TABLE 96 PATENTS BY ASSIGNEE UTILIZING CONJUGATE VACCINE TECHNOLOGY, 2006 TO SEPTEMBER FIGURE 49 PATENTS BY ASSIGNEE UTILIZING CONJUGATE VACCINE TECHNOLOGY, 2006 TO SEPTEMBER TOXOID VACCINE TECHNOLOGY TABLE 97 PATENTS BY ASSIGNEE UTILIZING TOXOID VACCINE TECHNOLOGY, 2006 TO SEPTEMBER FIGURE 50 PATENTS BY ASSIGNEE UTILIZING TOXOID VACCINE TECHNOLOGY, 2006 TO SEPTEMBER RECOMBINANT/RDNA VACCINE TECHNOLOGY TABLE 98 PATENTS BY ASSIGNEE UTILIZING RECOMBINANT/RDNA VACCINE TECHNOLOGY, 2006 TO SEPTEMBER FIGURE 51 PATENTS BY ASSIGNEE UTILIZING RECOMBINANT/RDNA VACCINE TECHNOLOGY, 2006 TO SEPTEMBER SUBUNIT VACCINE TECHNOLOGY TABLE 99 PATENTS BY ASSIGNEE UTILIZING SUBUNIT VACCINE TECHNOLOGY, 2006 TO SEPTEMBER
13 FIGURE 52 PATENTS BY ASSIGNEE UTILIZING SUBUNIT VACCINE TECHNOLOGY, 2006 TO SEPTEMBER OTHER/COMBINED VACCINE TECHNOLOGY TABLE 100 PATENTS BY ASSIGNEE UTILIZING OTHER/COMBINED VACCINE TECHNOLOGY, 2006 TO SEPTEMBER FIGURE 53 PATENTS BY ASSIGNEE UTILIZING OTHER/COMBINED VACCINE TECHNOLOGY, 2006 TO SEPTEMBER CHAPTER TWELVE: CURRENT SITUATION OF THE GLOBAL VACCINES MARKET FACTS ABOUT THE GLOBAL VACCINES MARKET FACTORS AFFECTING THE SALES OF VACCINES COMPETITION COST TRENDS IMMUNIZATION FUNDING GLOBAL IMMUNIZATION VISION AND STRATEGY (GIVS) TABLE 101 AIMS OF GIVS TABLE 102 GOALS OF GIVS TABLE 103 STRATEGIES OF GIVS CURRENT SITUATION TABLE 104 GLOBAL FUNDING GAP BY REGION FOR IMMUNIZATION WORK, ($ MILLIONS) VACCINE PREVENTABLE DISEASES UPDATE CURRENT VACCINE PRIORITIZATION TABLE 105 VACCINE PRIORITIZATION, CURRENT AND FUTURE (PROPOSED) VACCINE MILESTONES TABLE 106 VACCINE MILESTONES INFLUENZA VIRUS VACCINES UPDATE FOR THE 2010 THROUGH 2011 SEASON TABLE 107 INFLUENZA VACCINES FOR THE SEASON CHAPTER THIRTEEN: COMPANY PROFILES ADVAXIS BAYER ANIMAL HEALTH BUL BIO NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES LTD. (BB NCIPD LTD.) BHARAT BIOTECH BIO FARMA BIOLOGICAL E. LIMITED BIO MANGUINHOS BIOPROPERTIES
14 BOEHRINGER INGELHEIM VETMEDICA, INC CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY CEVA SANTE ANIMALE COLORADO SERUM COMPANY CRUCELL CSL LTD ELI LILLY & CO EMERGENT BIOSOLUTIONS FATRO GLAXOSMITHKLINE GREEN CROSS HAFFKINE BIO PHARMACEUTICAL CORPORATION LTD INDOVAX INSTITUT PASTEUR DE DAKAR INTERCELL JAPAN BCG LABORATORY KING PHARMACEUTICALS INC LOHMANN INTERNATIONAL MEDIMMUNE MERCK & CO., INC NIPPON BIOLOGICALS, INC NOVARTIS AG PANACEA BIOTEC PFIZER INC ROMVAC SANOFI AVENTIS (SANOFI PASTEUR) SERUM INSTITUTE OF INDIA LTD STATENS SERUM INSTITUT THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY VENTRI BIOLOGICALS ZYDUS CADILA APPENDIX I ABBREVIATIONS ABBREVIATIONS (CONTINUED)
Vaccine Technologies and Global Markets
A BCC Research Pharmaceutical Report and Global Markets PHM014D Use this report to: Learn about the strengths and weaknesses of each category of human and veterinary vaccine to prevent or treat infectious
More informationCHAPTER ONE: EXECUTIVE SUMMARY. The Global Vaccine Industry CHAPTER TWO: INTRODUCTION TO VACCINES
CHAPTER ONE: EXECUTIVE SUMMARY The Global Vaccine Industry o Scope and Methodology o Overview o Pediatric Preventative Vaccines o The Market o Adult Preventative Vaccines o The Market o Total Market o
More informationTable Of Contents Executive Summary Introduction to Vaccines Pediatric Preventive Vaccines
Table Of Contents Executive Summary THE GLOBAL VACCINES INDUSTRY Scope and Methodology Overview Pediatric Preventative Vaccines THE MARKET Adult Preventative Vaccines THE MARKET TOTAL MARKET ISSUES AND
More informationHow and Why Vaccines Are Developed by Industry. Stanley A. Plotkin
How and Why Vaccines Are Developed by Industry Stanley A. Plotkin Merieux 2012 1 Why Vaccines are Different than Drugs 1) Given to healthy people, high safety required 2) Larger governmental role 3) Low
More informationREGULATORY UPDATES: APPROVAL, DENIALS AND AGREEMENTS REGULATORY UPDATES: APPROVAL, (CONTINUED)... 38
CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED
More informationTHYROID HORMONE THERAPY TABLE 21 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR FIGURE 4 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 1 SCOPE OF REPORT... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ANALYST S CREDENTIALS...
More informationBRIC DIABETES DRUGS MARKET
BRIC DIABETES DRUGS MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d M a
More informationDNA VACCINES: TECHNOLOGIES AND GLOBAL MARKETS
DNA VACCINES: TECHNOLOGIES AND GLOBAL MARKETS BIO067B July 2014 Jon Evans Project Analyst ISBN: 1-56965-883-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within
More informationJAK AND PI3K SIGNALING PATHWAY MARKETS
JAK AND PI3K SIGNALING PATHWAY MARKETS PHM168A April 2014 Shalini Shahani Dewan Project Analyst ISBN: 1-56965-793-9 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationREFERENCE CODE GDHC1032FPR PUBLICAT ION DATE M ARCH 2014 PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES - CURRENT AND FUTURE PLAYERS
REFERENCE CODE GDHC1032FPR PUBLICAT ION DATE M ARCH 2014 PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES - Executive Summary Human PapillomaVirus (HPV) Vaccine Sales Expected to Grow Modestly During the Forecast
More informationCANCER VACCINES: TECHNOLOGIES AND GLOBAL MARKETS
CANCER VACCINES: TECHNOLOGIES AND GLOBAL MARKETS PHM173A January 2015 Shalini Shahani Dewan Project Analyst ISBN: 1-62296-008-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationPractical Applications of Immunology. Chapter 18
Practical Applications of Immunology Chapter 18 I. Vaccines A. Definition A suspension of organisms or fractions of organisms that is used to induce immunity (immunologic memory). The mechanism of memory
More informationCHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 1 MARKET ANALYSES AND FORECASTS... 2 INTENDED AUDIENCE... 2 INFORMATION SOURCES... 2 ANALYST
More informationInfluenza Vaccination Market Research Report Global Forecast till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/1621 Influenza Vaccination Market Research Report Global Forecast till 2023 Report / Search Code: MRFR/HC/1090-HCRR
More informationGLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES
GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES PHM005C January 2013 Peggy Lehr Project Analyst ISBN: 0-89336-646-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481
More informationGlobal Coverage. Regional Coverage. Company Coverage. Country Coverage. Global Coverage Regional Coverage Country Coverage
Global Influenza Drugs and Vaccines Market By Drugs (Zanamivir, Oseltamivir Phosphate, Peramivir), By Vaccine (Trivalent, Quadrivalent): Analysis By Region, By Country: Opportunities and Forecast (2016-2021)
More informationANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS
ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS PHM119B September 2016 Anuj Pathak Project Analyst ISBN: 1-62296-345-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
More informationREFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Gardasil: Key Metrics in Nine Major
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationV3P: Region Fact Sheet
V3P: Region Fact Sheet Highlights The 1 region market is 15% of the global market in volume and 63% in value. The regional vaccine procurement habits are different from the rest of the world in several
More informationCHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Total Size and Growth of the Market Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
More informationTransforming The Approach to Vaccines and Protein- Based Therapeutics. Alain Doucet, Ph.D. Manager, Process Development, Medicago
Transforming The Approach to Vaccines and Protein- Based Therapeutics Alain Doucet, Ph.D. Manager, Process Development, Medicago 2018-08-15 1 Medicago Overview 2 Novel Technologies 3 Robust Pipeline 2
More informationV3P: Region Fact Sheet
V3P: Region Fact Sheet Highlights The 1 region market is 4% of the global market in volume and 5% in value. The regional vaccine procurement habits are different from the rest of the world in several ways,
More informationStanley A. Plotkin ADVAC /10/2010 2:35 PM
How and dwh Why Vaccines are Made Stanley A. Plotkin ADVAC 1 2010 5/10/2010 2:35 PM 1 Vaccines 1. History of vaccination 2. The vaccine industry 3. Why vaccines are developed 4. The current problems of
More informationREFERENCE CODE GDHC334DFR PUBLICAT ION DATE J ANU ARY 2014 ENGERIX-B (PROPHYLACTIC HEPATITIS B VIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC334DFR PUBLICAT ION DATE J ANU ARY 2014 ENGERIX-B (PROPHYLACTIC HEPATITIS B VIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary The table below provides a summary
More informationMEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS. PHM154A September Anand Gijare Project Analyst ISBN:
MEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS PHM154A September 2013 Anand Gijare Project Analyst ISBN: 1-56965-544-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301
More informationContraceptives: Technologies and Global Markets
A BCC Research Healthcare Report HLC085A Use this report to: Learn how shifting demographic and sociological factors such as population growth, proportion of young population, and perceptions about family
More informationGlobal Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential Forecast to 2023
Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential Forecast to 2023 Global Psoriasis Pipeline Drugs Industry Sizing, Growth and Forecast
More informationCHAPTER FIVE: COMMERCIAL APPLICATIONS TABLE 12 COMMERCIAL AMINO ACIDS BY USE... 35
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 1 SCOPE OF REPORT... 2 METHODOLOGY AND INFORMATION SOURCES... 2 ANALYST CREDENTIALS...
More informationVaccines: Poised To Deliver Significant Growth in Emerging Markets
Vaccines: Poised To Deliver Significant Growth in Emerging Markets 4 th DVFA Symposium Life Science Pierre Morgon Vice-President, Franchise & Global Marketing Operations, Sanofi Pasteur Frankfurt, May
More informationREFERENCE CODE GDHC1155DFR PUBLICAT ION DATE SEPTEMBER 2013 NIMENRIX (MENINGOCOCCAL VACCINES) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC1155DFR PUBLICAT ION DATE SEPTEMBER 2013 NIMENRIX (MENINGOCOCCAL VACCINES) Executive Summary Nimenrix: Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US 5EU Japan
More informationINCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS
INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS PHM162A February 2015 Kim Lawson Project Analyst ISBN: 1-62296-047-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA
More informationCurrent needs for Vaccine R & D and Implementation in Developing Countries : Norwegian & Intl. Partners Contribution
Current needs for Vaccine R & D and Implementation in Developing Countries : Norwegian & Intl. Partners Contribution by DR.SURESH S. JADHAV Executive Director Serum Institute of India Ltd/Pune & President
More informationTABLE 4 U.S. TEETH CLEANING VISITS BY SELECTED CHARACTERISTICS (%) TABLE 4 (CONTINUED) FIGURE 2 U.S. POPULATION WITH TEETH CLEANING
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 1 METHODOLOGY... 2 ANALYST... 3 RELATED BCC STUDIES... 3 BCC ONLINE SERVICES... 3 DISCLAIMER...
More informationREFERENCE CODE GDHC1161DFR PUBLICAT ION DATE SEPTEMBER 2013 MENOMUNE (MENINGOCOCCAL VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC1161DFR PUBLICAT ION DATE SEPTEMBER 2013 MENOMUNE (MENINGOCOCCAL VACCINES) - Executive Summary Menomune: Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US 5EU
More informationCHAPTER THREE: INDUSTRY OVERVIEW... 6 HISTORICAL PERSPECTIVE OF THE MENTAL HEALTH INDUSTRY... 6 HISTORICAL PERSPECTIVE OF THE (CONTINUED)...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR STUDY... 1 SCOPE OF STUDY... 1 METHODOLOGY AND INFORMATION SOURCES... 2 ANALYST CREDENTIALS... 2 RELATED BCC REPORTS... 2 DISCLAIMER...
More informationSeasonal vaccine approval - EUROPEAN UNION -
Seasonal vaccine approval - EUROPEAN UNION - Jim Robertson National Institute for Biological Standards and Control National Institute for Biological Standards and Control Assuring the quality of biological
More informationVaccines and other immunological antimicrobial therapy 1
Vaccines and other immunological antimicrobial therapy 1 Vaccines Vaccine: a biological preparation that provides active acquired immunity to a particular disease. Vaccine typically contains an agent that
More informationManaging cost considerations and access to technology for cost effective vaccine manufacture in developing countries.
Managing cost considerations and access to technology for cost effective vaccine manufacture in developing countries. Amol R. Dindokar Serum Institute of India ltd. Overview Disease Control Priorities
More informationGlobal Influenza Vaccine Market: Industry Analysis & Outlook
Industry Research by Koncept Analytics Global Influenza Vaccine Market: Industry Analysis & Outlook ----------------------------------------- January 2017 1 Executive Summary Influenza, also known as flu,
More informationBiotechnology-Based Vaccines. Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel:
Biotechnology-Based Vaccines Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel: 4677363 aalshamsan@ksu.edu.sa Objectives of this lecture By the end of this lecture you will be able to: 1.
More informationStainless-steel vs Single-use: The Vaccines Perspective
Stainless-steel vs Single-use: The Vaccines Perspective CMO-Biomanufacturer Panel Tue 21 April, Noon-1:30pm, Exhibit Hall Daniel C.Vellom, PhD Sr. Director Global Technology Innovation 2015 INTERPHEX 1
More informationGRNVAC DCVax-Brain AGS Glionix CYT004-MelQbG CDX-110 (PF ) GI TABLE 23 OCCURRENCE OF
CHAPTER ONE: INTRODUCTION.1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 1 SCOPE OF REPORT... 2 METHODOLOGY... 2 INFORMATION SOURCES... 3 AUTHOR S CREDENTIALS...
More informationVACCINATION. DR.FATIMA ALKHALEDY M.B.Ch.B;F.I.C.M.S/C.M.
VACCINATION DR.FATIMA ALKHALEDY M.B.Ch.B;F.I.C.M.S/C.M. IMMUNIZATION Immunization is defined as the procedure by which the body is prepared to fight against a specific disease. It is used to induce the
More informationCrucell a compelling investment case
Crucell a compelling investment case Investor Presentation March 2008 Disclaimer The presentation contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain
More informationChina Human Vaccine Industry Report, Jun. 2016
China Human Vaccine Industry Report, 2016-2020 Jun. 2016 STUDY GOAL AND OBJECTIVES This report provides the industry executives with strategically significant competitor information, analysis, insight
More informationTechnology Transfer from the Perspective of IFPMA vaccine members
Technology Transfer from the Perspective of IFPMA vaccine members WHO Workshop on Technology Transfer for Local Manufacturing Capacity of Vaccines Michael Watson (Sanofi Pasteur) Chair of IFPMA Biologicals
More informationREFERENCE CODE GDHC1013FPR PUBLICAT ION DATE AUGUST 2013 MENINGOCOCCAL VACCINES - CURRENT AND FUTURE PLAYERS
REFERENCE CODE GDHC1013FPR PUBLICAT ION DATE AUGUST 2013 MENINGOCOCCAL VACCINES - Executive Summary Meningococcal Vaccines: Key Metrics in the Nine Major Pharmaceutical Markets 2012 Epidemiology Targeted
More informationACIP Meeting Update, New Recommendations and Pending Influenza Season
ACIP Meeting Update, New Recommendations and Pending Influenza Season February 17 th 2011 www.immunizetexas.com ACIP Upcoming Agenda and New Recommendations ACIP (February 23-24 th 2011) Topics for meeting
More informationHow and Why Vaccines are Made. Stanley A. Plotkin
How and Why Vaccines are Made Stanley A. Plotkin Levine 2017 January 23, 2017 Vaccinology A combination of: Microbiology Immunology Epidemiology Public Health and Pharmacy 2 The impact of vaccination on
More informationMedicago: transforming the approach to vaccines and protein-based therapeutics. Bruce D. Clark PhD President & CEO September 27, 2017
Medicago: transforming the approach to vaccines and protein-based therapeutics Bruce D. Clark PhD President & CEO September 27, 2017 Medicago Overview Focus Manufacturing technology Vaccine technology
More informationREFERENCE CODE GDHC68PIDR PUBLICATION DATE JANUARY 2014 PROPHYLACTIC HEPATITIS B VIRUS VACCINES - GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC68PIDR PUBLICATION DATE JANUARY 2014 PROPHYLACTIC HEPATITIS B VIRUS VACCINES - GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Prophylactic HBV Vaccines: Key Metrics
More informationVaccines on the Global Scale
Vaccines on the Global Scale Learning from the past and aiming at the future Edwin J. Asturias, MD Associate Professor of Pediatrics and Epidemiology Director for Latin America Center for Global Health,
More informationOperatory Units TABLE 20 SELECT MANUFACTURERS AND DISTRIBUTORS OF DENTAL FURNITURE TABLE 20 (CONTINUED) Cavity Preparation Systems
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE AND FORMAT... 1 METHODOLOGY... 1 RELATED BCC STUDIES... 2 ANALYST CREDENTIALS... 2 BCC ON-LINE SERVICES...
More informationGlobal Vaccine Market Features and Trends
Global Vaccine Market Features and Trends Miloud Kaddar Senior Adviser, Health Economist 1 WHO, IVB, Geneva GLOBAL VACCINE MARKET MAIN FEATURES OF THE VACCINE MARKET? NEW TRENDS SINCE 2000? IMPLICATIONS?
More informationAndrew Kroger, MD, MPH National Center for Immunization and Respiratory Diseases MCH & Immunization Conference Anchorage, AK September 28, 2010
2010 Immunization Update Andrew Kroger, MD, MPH National Center for Immunization and Respiratory Diseases MCH & Immunization Conference Anchorage, AK September 28, 2010 Disclosures No financial conflict
More informationGlobal HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country ( )
Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country (2017-2022) By Region- North America, Europe, APAC and RoW By Country - United
More informationADULT ENTERAL NUTRITION PARENTERAL NUTRITION U.S. REGULATORY ENVIRONMENT THE INFANT FORMULA ACT OF The 1986 Amendments
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE AND FORMAT... 1 METHODOLOGY AND INFORMATION SOURCES... 2 ANALYST CREDENTIALS... 2 RELATED BCC REPORTS...
More informationAnnex 1. WHO Recommendations, Guidelines and other documents related to the manufacture and quality control of biological substances used in medicine
WHO related to the manufacture and quality control of biological substances used in medicine WHO are intended to provide guidance to those responsible for the production of biological substances as well
More informationVaccination Update. Pregnancy. 24-May-17. Disclosures. Overview. Paul Van Buynder Professor, Griffith University Chairman, Immunisation Coalition
Vaccination Update Paul Van Buynder Professor, Griffith University Chairman, Immunisation Coalition Disclosures I have been involved in vaccine studies funded by CSL, Sanofi Pasteur, Merck and Novartis
More informationCHAPTER FOUR: MARKET SIZE AND GROWTH SLEEP MEDICATIONS MARKET PRESCRIPTION... 40
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR STUDY... 1 SCOPE OF STUDY... 1 METHODOLOGY AND INFORMATION SOURCES... 2 ANALYST CREDENTIALS... 2 RELATED BCC REPORTS... 2 BCC
More informationGLOBAL MARKETS FOR DIABETES THERAPEUTICS AND DIAGNOSTICS
GLOBAL MARKETS FOR DIABETES THERAPEUTICS AND DIAGNOSTICS HLC029D January 2013 Paul Evers Project Analyst ISBN: 0-89336-238-7 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301
More informationBOTANICAL AND PLANT-DERIVED DRUGS: GLOBAL MARKETS
BOTANICAL AND PLANT-DERIVED DRUGS: GLOBAL MARKETS BIO022G August 2015 Kim Lawson Project Analyst ISBN: 1-62296-134-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationChina Human Vaccine Industry Report, May 2012
China Human Vaccine Industry Report, 2011-2012 May 2012 STUDY GOAL AND OBJECTIVES This report provides the industry executives with strategically significant competitor information, analysis, insight and
More informationOrgan Transplantation Market Research Report- Global Forecast Till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/915 Organ Transplantation Market Research Report- Global Forecast Till 2023 Report / Search Code: MRFR/HC/0410-HCRR
More informationREFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013 XELJANZ (PSORIASIS) - Executive Summary Table below presents key metrics for Xeljanz (tofacitinib) in seven of the nine major pharmaceutical markets
More informationVaccine Industry in India An Emerging Global Hub
Vaccine Industry in India An Emerging Global Hub Authors: Dr. Banu Priya C, Pugazhenthi. E, Shreyas Rajan, Dr. Neelam Malhotra, Mallikarjun bidari Global Outlook Asia is emerging as the vaccine hub of
More informationImmunity and how vaccines work
Immunity and how vaccines work Dr Mary O Meara National Immunisation Office Objectives of session An understanding of the following principles Overview of immunity Different types of vaccines and vaccine
More informationU.S. Readiness for Pandemics
0 U.S. Readiness for Pandemics 5 th National Emergency Management Summit Brooklyn, NY September 15, 2011 Robin Robinson, Ph.D. Deputy Assistant Secretary for Preparedness & Response (HHS/ASPR) Director
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationNew study: Tuberculosis vaccine treatment market research forecast to 20...
1 of 9 10-Dec-2016 3:11 PM Home Technology Company Directory Share your news Membership Market Research Advertise About Login Medical Health & Life Science Research News New study: Tuberculosis vaccine
More informationBenefit Interpretation
Benefit Interpretation Subject: Part B vs. Part D Vaccines Issue Number: BI-039 Applies to: Medicare Advantage Effective Date: May 1, 2017 Attachments: Part B Vaccines Diagnosis Code Limits Table of Contents
More informationNovember 13, 2009 Licensure, Evaluation, and Adverse Event Monitoring of the 2009 H1N1 Influenza Vaccine By Matthew Watson and Jennifer Nuzzo
www.upmc-biosecurity.org www.upmc-cbn.org November 13, 2009 Licensure, Evaluation, and Adverse Event Monitoring of the 2009 H1N1 Influenza Vaccine By Matthew Watson and Jennifer Nuzzo In response to the
More informationLETTERS FOR ISSUE ON
S FOR ISSUE ON 01.09.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE 1. M/S TYCHE INDUSTRIES LTD., ANDHRA PRADESH, INDIA IMPORT S. NAME OF APPLICANT DIARY TYPE OF 1. PIRAMAL ENTERPRISES LTD. 25471 APPROVAL
More informationCreating VaCCines, ProteCting Life
Creating VaCCines, ProteCting Life PreVenting Disease through VaCCination a Constant BattLe Immunization has been a great public health success story. The lives of millions of children have been saved,
More informationCHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Size and Growth of the Market Issues and trends Leading Competitors CHAPTER TWO: INTRODUCTION AND OVERVIEW Definition of Pain Magnitude
More informationGlobal Health Policy: Vaccines
Global Health Policy: Vaccines Edwin J. Asturias Senior Investigator Colorado School of Public Health Department of Pediatrics Children s Hospital Colorado UNIVERSITY OF COLORADO COLORADO STATE UNIVERSITY
More informationTHERAPIES AND BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE
THERAPIES AND BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE PHM125A January 2013 Willem Westra Project Analyst ISBN: 0-89336-715-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215,
More informationGuidelines for Vaccinating Pregnant Women
Guidelines for Vaccinating Pregnant Women March 2012 Guidelines for Vaccinating Pregnant Women Abstracted from recommendations of the Advisory Committee on Immunization Practices (ACIP) MARCH 2012 Risk
More informationCytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019
Reference Code: GDHC504PRT Publication Date: January 2013 Cytomegalovirus Infections: Key Metrics in Seven Major Pharmaceutical Markets 2012 Epidemiology* Prevalent population (CMV prevalent cases in general
More informationCURRENT DEVELOPMENT IN PEDIATRIC VACCINATION
Univ.-Prof. Dr. med. Heinz-J. SCHMITT Senior Medical Director, Pfizer Vaccines Europe Thessaloniki, February 20th, 2018 CURRENT DEVELOPMENT IN PEDIATRIC VACCINATION Selected Case Fatality Rates Germany,
More informationGASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS. HLC174A October Usha Nagavarapu Project Analyst
GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS HLC174A October 2015 Usha Nagavarapu Project Analyst ISBN: 1-62296-167-6 BCC Research 49 Walnut Park, Building 2 Wellesley,
More informationCHAPTER FIVE: COMMERCIAL APPLICATIONS TABLE 12 COMMERCIAL AMINO ACIDS BY USE... 35
CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 1 SCOPE OF REPORT... 2 INFORMATION SOURCES... 2 ANALYST CREDENTIALS... 3 RELATED BCC REPORTS...
More informationTarget Design and Immunogenicity
Target Design and Immunogenicity 03-18-2013 Vidadi Yusibov New Cells, New Vaccines VII: From Protein to Product Vaccine Products Conventional vaccines: Inactivated Live, attenuated Toxoid Recombinant Subunit
More informationStatus of Registration Certificate (Form 41) of Human Vaccines issued from 01/03/2015 to 29/05/2015. Human vaccines
Status of Registration Certificate (Form 41) of Human Vaccines issued from 01/03/2015 to 29/05/2015 S. No. Firm Name of Formulation Registration Certificate No. & Validity 1. M/s. Nirlac Chemicals,14 th
More informationTB Vaccine Development Strategy Overview
TB Vaccine Development Strategy Overview October 28, 2014 Angeline Nanni, MBA, MS Aeras Director, Global Access TB is Mother Nature s number one killer over the past centuries TB is spread through the
More information1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast ( ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector
1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast (2006 ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector wise) (2005 ) 4. Worldwide Pediatric Vaccines Market Share
More informationTODAY S VACCINATION ECOSYSTEM STATUS MARKET-SHAPING PRINCIPLES, PRACTICE, IMPACT AND LESSONS LEARNT GAVI PERSPECTIVE
TODAY S VACCINATION ECOSYSTEM STATUS MARKET-SHAPING PRINCIPLES, PRACTICE, IMPACT AND LESSONS LEARNT GAVI PERSPECTIVE Aurélia Nguyen Tuesday 20 January 2015, Veyrier-du-Lac, France www.gavi.org AGENDA Market
More informationPrevention and Treatment of Prostate Cancer: Technologies and Global Markets March Usha Nagavarapu. Report # PHM113B
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March 2017 Usha Nagavarapu Report # PHM113B Table of Contents Chapter 1 Introduction... 1 Introduction... 1 Study goals and
More informationCurrent and future market dynamics overview
OVERVIEW Catalyst Summary EXECUTIVE SUMMARY Strategic scoping and focus Datamonitor key findings Related reports MARKET DEFINITION Published diabetes reports Market definition for antidiabetic drugs Forecast
More informationPHM029D - Antifungal Drugs: Technologies and Global Markets TABLE OF CONTENTS
TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 1 STUDY GOALS AND OBJECTIVES 1 REASONS FOR DOING THIS STUDY 1 INTENDED AUDIENCE 2 SCOPE OF REPORT 2 METHODOLOGY 2 INFORMATION SOURCES 2 ANALYST CREDENTIALS 3 RELATED
More informationThe Crisis in. Vaccine Development
The Crisis in Vaccine Development Stanley A. Plotkin 1 Annecy 2015 The Evolution of the Vaccine Industry 1. 18 th -19 th Centuries Pioneers 2. 1900-1950 National Producers 3. 1960-1980 Globalization 4.
More informationMedical Coverage Guidelines are subject to change as new information becomes available.
IMMUNIZATIONS Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline must
More informationCOPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global
COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global Opportunity Analysis and Industry Forecasts, 2015-2022 COPD and
More informationStandards and beyond: challenges of application of old methods to next generation products. Elena Semenova, Penny Post, Tim Fields, Manon Cox
Standards and beyond: challenges of application of old methods to next generation products Elena Semenova, Penny Post, Tim Fields, Manon Cox March 25, 2014 Recombinant Flu vaccines Propagation of the influenza
More informationChina Human Vaccine Industry Report, Mar. 2015
China Human Vaccine Industry Report, 2015-2018 Mar. 2015 STUDY GOAL AND OBJECTIVES This report provides the industry executives with strategically significant competitor information, analysis, insight
More informationImmunization Guidelines For the Use of State Supplied Vaccine July 1, 2011
DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,
More informationGuidelines for Vaccinating Pregnant Women
Guidelines for Vaccinating Pregnant Women April 2013 Guidelines for Vaccinating Pregnant Women Abstracted from recommendations of the Advisory Committee on Immunization Practices (ACIP) April 2013 Risk
More informationWhat's the future for animal vaccines?
What's the future for animal vaccines? Diego G. Diel, DVM, MS, PhD Assistant Professor Department of Veterinary and Biomedical Sciences South Dakota State University E-mail: diego.diel@sdstate.edu Outline
More informationVACCINE PRODUCTION IN DEVELOPING COUNTRIES: AN ECONOMIC EVALUATION
VACCINE PRODUCTION IN DEVELOPING COUNTRIES: AN ECONOMIC EVALUATION Syarifah Liza Munira, PhD Department of Economics, Faculty of Economics and Business, Universitas Indonesia liza.munira@ui.ac.id; lizamunira@yahoo.com
More information